US-based biotech Eradivir announced that a Phase 1/2a trial of its EV25 intranasal antiviral for the treatment of influenza demonstrated that a single 300 mg dose resulted in a significant reduction in lower respiratory tract infection and a 98% reduction in median viral load AUC compared to placebo. The company said that it intends to advance EV25 into a Phase 2b study in the US and Europe that is expected to enroll up to 375 subjects during the 2026-27 flu season.
According to Eradivir, EV25 was generally safe and well-tolerated, with PK data showing rapid absorption and linear dose response. In the H3N2 challenge study portion of the trial, the company said, EV25 produced a significant reduction in reported symptom duration and severity. In addition, 85.7% of those in the placebo group developed a lower respiratory tract infection versus only 35.7% in the EV25 group.
Eradivir’s pipeline also includes candidates for the treatment of RSV and Dengue fever based on Eradivir’s BAiT (Bispecific Antigenic immuno-Therapy) platform. The company says that the technology “recruits endogenous antibodies to target virus and infected cells to clear the disease. By altering the targeting portion of the molecule, the platform can be leveraged to treat a myriad of diseases.”
Eradivir CEO Martin Low commented, “We are thrilled that the Phase 2a results showed that EV25 was well tolerated and demonstrated significant reduction in both viral loads and influenza symptoms. These results are encouraging and support the continued development of EV25 as a potential treatment for influenza. We look forward to advancing EV25 into a larger Phase 2b trial to further evaluate its efficacy.”
Read the Eradivir press release
